Literature DB >> 15070976

Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims.

Alexander Tenenbaum, Enrique Z Fisman, Michael Motro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15070976     DOI： 10.1210/jc.2003-032038

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  2 in total

Review 1.  Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

Authors:  Alexander Tenenbaum; Enrique Z Fisman; Michael Motro; Yehuda Adler
Journal:  Cardiovasc Diabetol       Date:  2006-09-26       Impact factor: 9.951

2.  Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Authors:  Alexander Tenenbaum; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2004-12-01       Impact factor: 9.951
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.